Mycobacteria-specific cytokine responses detect tuberculosis infection and distinguish latent from active tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 4, 2015, Pages 485-499

  Tebruegge, Marc ^a,b,c,d   Dutta, Binita ^c   Donath, Susan ^a,b,c   Ritz, Nicole ^a,b,c,e   Forbes, Benjamin ^c   Camacho Badilla, Kattia ^b   Clifford, Vanessa ^a,c   Zufferey, Christel ^c   Robins Browne, Roy ^a,c   Hanekom, Willem ^f   Graham, Stephen M ^a,c,g   Connell, Tom ^a,b,c   Curtis, Nigel ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g Centre for International Child Health   (Australia)

Author keywords

Biomarker; Child; Cytokines; Diagnosis; Tuberculosis

Indexed keywords

BIOLOGICAL MARKER; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN DERIVATIVE;

ADOLESCENT; ARTICLE; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; HUMAN; LATENT TUBERCULOSIS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS; BLOOD; COHORT ANALYSIS; DIFFERENTIAL DIAGNOSIS; FEMALE; MALE; PREDICTIVE VALUE; PRESCHOOL CHILD;

ADOLESCENT; BIOLOGICAL MARKERS; CHEMOKINE CCL4; CHEMOKINE CXCL10; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; LATENT TUBERCULOSIS; MALE; PREDICTIVE VALUE OF TESTS; ROC CURVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940065181     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201501-0059OC     Document Type: Article

References (53)

1. Dye C. Global epidemiology of tuberculosis. Lancet 2006;367:938-940.
2. World Health Organization. Global tuberculosis report 2013 [accessed 2015 Jul 22]. Available from: http://www.who.int/tb/publications/global-report/en/
3. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med 2006;173:1078-1090.
4. Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B, Boehme CC, Zemanay W, Zar HJ. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011;11:819-824.
5. Tebruegge M, Connell T, Curtis N. Tuberculosis in children. N Engl J Med 2012;367:1568.
6. Tebruegge M, Ritz N, Curtis N, Shingadia D. Diagnostic tests for childhood tuberculosis - past imperfect, present tense and future perfect? Pediatr Infect Dis J [online ahead of print] 22 Jun 2015; DOI: 10.1097/INF.0000000000000796.
7. Tebruegge M, Connell T, Ritz N, Bryant PA, Curtis N. Discordance between TSTs and IFN-gamma release assays: the role of NTM and the relevance of mycobacterial sensitins. Eur Respir J 2010;36:214-215.
8. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356:1099-1104.
9. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, Bossink A, Dheda K, Diel R, Dominguez J, et al. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011;37:100-111.
10. Connell T, Tebruegge M, Ritz N, Curtis N. Interferon-gamma release assays for the diagnosis of tuberculosis. Pediatr Infect Dis J 2009;28:758-759.
11. Connell TG, Tebruegge M, Ritz N, Bryant P, Curtis N. The potential danger of a solely interferon-gamma release assay-based approach to testing for latent Mycobacterium tuberculosis infection in children. Thorax 2011;66:263-264.
12. Connell TG, Tebruegge M, Ritz N, Bryant PA, Leslie D, Curtis N. Indeterminate interferon-gamma release assay results in children. Pediatr Infect Dis J 2010;29:285-286.
13. Haustein T, Ridout DA, Hartley JC, Thaker U, Shingadia D, Klein NJ, Novelli V, Dixon GL. The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J 2009;28:669-673.
14. Tebruegge M, de Graaf H, Sukhtankar P, Elkington P, Marshall B, Schuster H, Patel S, Faust SN. Extremes of age are associated with indeterminate QuantiFERON-TB gold assay results. J Clin Microbiol 2014;52:2694-2697.
15. Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001;1:20-30.
16. Ruhwald M, Ravn P. Biomarkers of latent TB infection. Expert Rev Respir Med 2009;3:387-401.
17. Clifford V, Zufferey C, Street A, Denholm J, Tebruegge M, Curtis N. Cytokine biomarkers for monitoring anti-tuberculous therapy: a systematic review. Tuberculosis (Edinb) 2015;95:217-228.
18. Naseer A, Naqvi S, Kampmann B. Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin skin testing. Eur Respir J 2007;29:1282-1283.
19. Ritz N, Yau C, Connell TG, Tebruegge M, Leslie D, Curtis N. Absence of interferon-gamma release assay conversion following tuberculin skin testing. Int J Tuberc Lung Dis 2011;15:767-769.
20. Globan M, Fyfe J. Mycobacterium tuberculosis complex. In: Schuller M, Sloots TP, James GS, Halliday CL, Carter IWJ, editors. PCR for clinical microbiology, 1st ed. New York, NY: Springer; 2010. pp. 165-170.
21. American Thoracic Society and the Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Official statement of the American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 2000;161:1376-1395.
22. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
23. Harari A, Rozot V, Bellutti Enders F, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calandra T, Blanchet CL, Jaton K, et al. Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011;17:372-376.
24. Alsleben N, Ruhwald M, Rüssmann H, Marx FM, Wahn U, Magdorf K. Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: a case-control study. Scand J Infect Dis 2012;44:256-262.
25. Armand M, Chhor V, de Lauzanne A, Guérin-El Khourouj V, Pédron B, Jeljeli M, Gressens P, Faye A, Sterkers G. Cytokine responses to quantiferon peptides in pediatric tuberculosis: a pilot study. J Infect 2014;68:62-70.
26. Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A, Cadogan E, Nahid P, Ferrari G, Stout JE. Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb) 2011;91:250-256.
27. Whittaker E, Gordon A, Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma? PLoS One 2008;3:e3901.
28. Yassin MA, Petrucci R, Garie KT, Harper G, Arbide I, Aschalew M, Merid Y, Kebede Z, Bawazir AA, Abuamer NM, et al. Can interferon-gamma or interferon-gamma-induced-protein-10 differentiate tuberculosis infection and disease in children of high endemic areas? PLoS One 2011;6:e23733.
29. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 2009;2:19.
30. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Kofoed K, Eugen-Olsen J, Ravn P. CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. Microbes Infect 2007;9:806-812.
31. Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H, Murphy M, Liao F, Farber J, Cassatella MA. Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 1999;162:4928-4937.
32. Colizzi V. In vivo and in vitro administration of interleukin 2-containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice. Infect Immun 1984;45:25-28.
33. Hubbard RD, Collins FM. Immunomodulation of mouse macrophage killing of Mycobacterium avium in vitro. Infect Immun 1991;59:570-574.
34. Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M, Mengoni F, Vanini V, Girardi E, Goletti D, D' Amelio R, et al. Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. Clin Microbiol Infect 2010;16:1282-1284.
35. Casey R, Blumenkrantz D, Millington K, Montamat-Sicotte D, Kon OM, Wickremasinghe M, Bremang S, Magtoto M, Sridhar S, Connell D, et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis. PLoS One 2010;5:e15619.
36. Chiappini E, Della Bella C, Bonsignori F, Sollai S, Amedei A, Galli L, Niccolai E, Del Prete G, Singh M, D'Elios MM, et al. Potential role of M. tuberculosis specific IFN-γ and IL-2 ELISPOT assays in discriminating children with active or latent tuberculosis. PLoS One 2012;7:e46041.
37. Krummel B, Strassburg A, Ernst M, Reiling N, Eker B, Rath H, Hoerster R, Wappler W, Glaewe A, Schoellhorn V, et al. Potential role for IL-2 ELISpot in differentiating recent and remote infection in tuberculosis contact tracing. PLoS One 2010;5:e11670.
38. Lighter-Fisher J, Peng CH, Tse DB. Cytokine responses to QuantiFERON® peptides, purified protein derivative and recombinant ESAT-6 in children with tuberculosis. Int J Tuberc Lung Dis 2010;14:1548-1555.
39. Wang S, Diao N, Lu C, Wu J, Gao Y, Chen J, Zhou Z, Huang H, Shao L, Jin J, et al. Evaluation of the diagnostic potential of IP-10 and IL-2 as biomarkers for the diagnosis of active and latent tuberculosis in a BCG-vaccinated population. PLoS One 2012;7:e51338.
40. Chegou NN, Detjen AK, Thiart L, Walters E, Mandalakas AM, Hesseling AC, Walzl G. Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting. PLoS One 2013;8:e64226.
41. Yu Y, Zhang Y, Hu S, Jin D, Chen X, Jin Q, Liu H. Different patterns of cytokines and chemokines combined with IFN-γ production reflect Mycobacterium tuberculosis infection and disease. PLoS One 2012;7:e44944.
42. Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MO. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS One 2010;5:e12365.
43. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006;10:1192-1204.
44. Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.TB in children. PLoS One 2008;3:e2624.
45. Connell TG, Curtis N, Ranganathan SC, Buttery JP. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax 2006;61:616-620.
46. Hill PC, Brookes RH, Adetifa IM, Fox A, Jackson-Sillah D, Lugos MD, Donkor SA, Marshall RJ, Howie SR, Corrah T, et al. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 2006;117:1542-1548.
47. Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009;22:403-409.
48. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2:CD008794.
49. Ruth JH, Bienkowski M, Warmington KS, Lincoln PM, Kunkel SL, Chensue SW. IL-1 receptor antagonist (IL-1ra) expression, function, and cytokine-mediated regulation during mycobacterial and schistosomal antigen-elicited granuloma formation. J Immunol 1996;156:2503-2509.
50. Lyadova IV, Tsiganov EN, Kapina MA, Shepelkova GS, Sosunov VV, Radaeva TV, Majorov KB, Shmitova NS, van den Ham HJ, Ganusov VV, et al. In mice, tuberculosis progression is associated with intensive inflammatory response and the accumulation of Gr-1 cells in the lungs. PLoS One 2010;5:e10469.
51. Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, Kornfeld H. Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect Immun 2002;70:1684-1693.
52. DeFife KM, Jenney CR, Colton E, Anderson JM. Cytoskeletal and adhesive structural polarizations accompany IL-13-induced human macrophage fusion. J Histochem Cytochem 1999;47:65-74.
53. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.